A Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift

Simply Wall St.04-15

AdvertisementStock move puts Phathom Pharmaceuticals in focus Recent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627700254?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-15 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627700254","market":"nz","top_or_hot":-1,"title":"A Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementStock move puts Phathom Pharmaceuticals in focus Recent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/a-look-at-phathom-pharmaceuticals-phat-valuation-after-recen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-15 11:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/a-look-at-phathom-pharmaceuticals-phat-valuation-after-recen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementStock move puts Phathom Pharmaceuticals in focus Recent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/a-look-at-phathom-pharmaceuticals-phat-valuation-after-recen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/a-look-at-phathom-pharmaceuticals-phat-valuation-after-recen","article_id":"2627700254","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/a-look-at-phathom-pharmaceuticals-phat-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627700254","pubTimestamp":1776222732,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Stock move puts Phathom Pharmaceuticals in focus\nRecent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing its current market value against the ongoing commercialization of VOQUEZNA therapies in the United States.\nSee our latest analysis for Phathom Pharmaceuticals.\nAt a share price of $12.67, recent trading has come after a 22.18% 1 month share price return but follows a 19.35% decline year to date and a 165.62%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHAT":"Phathom Pharmaceuticals"},"translate_title":"近期股票势头转变后Phathom Pharmaceuticals(PHAT)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1.5},"content_text":"AdvertisementStock move puts Phathom Pharmaceuticals in focus Recent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing its current market value against the ongoing commercialization of VOQUEZNA therapies in the United States. See our latest analysis for Phathom Pharmaceuticals. At a share price of $12.67, recent trading has come after a 22.18% 1 month share price return but follows a 19.35% decline year to date and a 165.62% 1 year total shareholder return. The pattern points to fading short term momentum following a longer term rebound. If you are comparing Phathom with other healthcare names tied to new treatments and data readouts, this could be a useful moment to scan for 34 healthcare AI stocks With Phathom trading at $12.67 compared with an average analyst target of $23.70 and a value score of 4, the question is whether the discount reflects risk or if the market is already pricing in future growth. Most Popular Narrative: 44.7% Undervalued Phathom's most followed valuation narrative sets a fair value of $22.90 per share, well above the last close at $12.67, and ties that gap to an aggressive earnings turnaround and margin improvement story.  Analysts are assuming Phathom Pharmaceuticals's revenue will grow by 75.1% annually over the next 3 years. Analysts assume that profit margins will increase from 289.5% loss making today to 25.4% in 3 years time.  Read the complete narrative. It may be useful to examine what kind of revenue ramp and margin shift would need to align for that valuation to work. The narrative refers to rapid scale, rising efficiency and a future earnings multiple below many peers. Readers may want to see which specific revenue and earnings milestones are built into that fair value and how sensitive the narrative could be if those milestones are not reached as expected. Result: Fair Value of $22.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on VOQUEZNA remaining on track and U.S. reimbursement improving, since setbacks in either area could quickly weaken the upbeat valuation story. Find out about the key risks to this Phathom Pharmaceuticals narrative. Another Angle on Valuation The SWS DCF model takes a different route from the analyst narrative and arrives at a future cash flow value of $177.01 per share, compared with the current $12.67 price. That very wide gap still flags PHAT as undervalued, but it also raises a question: is the cash flow path built into that model realistic for you? Look into how the SWS DCF model arrives at its fair value. PHAT Discounted Cash Flow as at Apr 2026Next Steps Given the mix of optimism and concern throughout this story, it makes sense to review the underlying numbers yourself and decide how comfortable you are with the balance between potential upside and downside. To help frame that decision, take a closer look at the 2 key rewards and 1 important warning sign. Looking for more investment ideas? If PHAT has your attention, do not stop here. Use this momentum to line up your next set of watchlist candidates with clear, data backed filters.  Target potential value opportunities by scanning 57 high quality undervalued stocks that match your quality and pricing checklist. Prioritize resilience by reviewing 74 resilient stocks with low risk scores if you want steadier profiles in your portfolio. Get ahead of the crowd by searching the screener containing 23 high quality undiscovered gems before they hit wider radars.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627700254","isCrawlerRequest":true}